Market Cap ₹19884 Cr.
Stock P/E 2058.9
P/B 2.5
Current Price ₹150.3
Book Value ₹ 59.8
Face Value 10
52W High ₹161.5
Dividend Yield 0.07%
52W Low ₹ 69.9
Piramal Pharma Ltd is a leading pharmaceutical company headquartered in Mumbai, India. The company provides a wide range of pharmaceutical solutions to customers in over 100 countries. Piramal Pharma specializes in drug discovery, development, and manufacturing across various therapeutic areas, including oncology, inflammation, metabolic disorders, and infectious diseases. The company's product portfolio includes APIs (Active Pharmaceutical Ingredients), formulations, contract manufacturing services, and over-the-counter (OTC) products. Piramal Pharma has a strong global presence with manufacturing facilities in India, the United States, and the United Kingdom. The company is committed to improving patient outcomes by leveraging its expertise in research and development, quality manufacturing, and supply chain management.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 1539 | 2131 | 1482 | 1720 | 1716 | 2164 | 1749 | 1911 | 1959 | 2552 |
| Other Income | 161 | 78 | 72 | 46 | 83 | 25 | 38 | 49 | 62 | 26 |
| Total Income | 1700 | 2210 | 1554 | 1766 | 1799 | 2188 | 1787 | 1961 | 2020 | 2579 |
| Total Expenditure | 1314 | 1733 | 1465 | 1547 | 1629 | 1812 | 1617 | 1646 | 1690 | 2022 |
| Operating Profit | 386 | 476 | 89 | 219 | 170 | 376 | 171 | 315 | 330 | 556 |
| Interest | 50 | 57 | 62 | 83 | 95 | 104 | 119 | 110 | 106 | 114 |
| Depreciation | 147 | 165 | 162 | 166 | 164 | 184 | 174 | 185 | 186 | 196 |
| Exceptional Income / Expenses | 0 | 0 | 0 | -7 | 0 | 0 | 0 | 0 | -32 | -31 |
| Profit Before Tax | 189 | 254 | -135 | -37 | -89 | 87 | -122 | 20 | 5 | 215 |
| Provision for Tax | 35 | 69 | -6 | 11 | 17 | 45 | -9 | 35 | 9 | 126 |
| Profit After Tax | 154 | 185 | -129 | -48 | -106 | 42 | -113 | -14 | -4 | 89 |
| Adjustments | 9 | 19 | 20 | 11 | 16 | 8 | 14 | 19 | 14 | 12 |
| Profit After Adjustments | 163 | 204 | -109 | -37 | -90 | 50 | -99 | 5 | 10 | 101 |
| Adjusted Earnings Per Share | 1.3 | 1.7 | -0.9 | -0.3 | -0.7 | 0.4 | -0.8 | 0 | 0.1 | 0.8 |
| #(Fig in Cr.) | Mar 2021 | Mar 2022 | Mar 2023 | TTM |
|---|---|---|---|---|
| Net Sales | 6315 | 6559 | 7082 | 8171 |
| Other Income | 164 | 276 | 225 | 175 |
| Total Income | 6479 | 6835 | 7307 | 8347 |
| Total Expenditure | 4887 | 5609 | 6453 | 6975 |
| Operating Profit | 1592 | 1225 | 853 | 1372 |
| Interest | 163 | 198 | 344 | 449 |
| Depreciation | 545 | 586 | 677 | 741 |
| Exceptional Income / Expenses | 18 | -15 | -7 | -63 |
| Profit Before Tax | 949 | 485 | -120 | 118 |
| Provision for Tax | 114 | 109 | 66 | 161 |
| Profit After Tax | 835 | 376 | -186 | -42 |
| Adjustments | 0 | 0 | 0 | 59 |
| Profit After Adjustments | 835 | 376 | -186 | 17 |
| Adjusted Earnings Per Share | 8.2 | 3.1 | -1.5 | 0.1 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 8% | 0% | 0% | 0% |
| Operating Profit CAGR | -30% | 0% | 0% | 0% |
| PAT CAGR | -149% | 0% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | 103% | NA% | NA% | NA% |
| ROE Average | -3% | 6% | 6% | 6% |
| ROCE Average | 2% | 7% | 7% | 7% |
| #(Fig in Cr.) | Mar 2021 | Mar 2022 | Mar 2023 |
|---|---|---|---|
| Shareholder's Funds | 5605 | 6697 | 6774 |
| Minority's Interest | 0 | 0 | 0 |
| Borrowings | 2339 | 2622 | 3384 |
| Other Non-Current Liabilities | 221 | 280 | 428 |
| Total Current Liabilities | 2591 | 3118 | 3851 |
| Total Liabilities | 10756 | 12717 | 14437 |
| Fixed Assets | 6105 | 6879 | 7469 |
| Other Non-Current Assets | 901 | 1686 | 2124 |
| Total Current Assets | 3749 | 4152 | 4843 |
| Total Assets | 10756 | 12717 | 14437 |
| #(Fig in Cr.) | Mar 2021 | Mar 2022 | Mar 2023 |
|---|---|---|---|
| Opening Cash & Cash Equivalents | 152 | 262 | 85 |
| Cash Flow from Operating Activities | 598 | 766 | 484 |
| Cash Flow from Investing Activities | -4480 | -1812 | -1339 |
| Cash Flow from Financing Activities | 3977 | 794 | 818 |
| Net Cash Inflow / Outflow | 94 | -251 | -37 |
| Closing Cash & Cash Equivalent | 262 | 85 | 53 |
| # | Mar 2021 | Mar 2022 | Mar 2023 |
|---|---|---|---|
| Earnings Per Share (Rs) | 8.2 | 3.1 | -1.53 |
| CEPS(Rs) | 13.55 | 7.92 | 4.01 |
| DPS(Rs) | 0 | 0 | 0 |
| Book NAV/Share(Rs) | 55.04 | 55.15 | 55.44 |
| Core EBITDA Margin(%) | 20.39 | 13 | 7.75 |
| EBIT Margin(%) | 15.89 | 9.35 | 2.76 |
| Pre Tax Margin(%) | 13.55 | 6.64 | -1.48 |
| PAT Margin (%) | 11.92 | 5.15 | -2.3 |
| Cash Profit Margin (%) | 19.71 | 13.17 | 6.05 |
| ROA(%) | 7.76 | 3.2 | -1.37 |
| ROE(%) | 14.9 | 6.11 | -2.77 |
| ROCE(%) | 13.06 | 7.1 | 1.95 |
| Receivable days | 82.08 | 83.94 | 80.7 |
| Inventory Days | 64.21 | 65.47 | 69.11 |
| Payable days | 162.72 | 144.76 | 149.81 |
| PER(x) | 0 | 0 | 0 |
| Price/Book(x) | 0 | 0 | 1.21 |
| Dividend Yield(%) | 0 | 0 | 0 |
| EV/Net Sales(x) | 0.55 | 0.74 | 1.89 |
| EV/Core EBITDA(x) | 2.2 | 3.98 | 15.66 |
| Net Sales Growth(%) | 0 | 3.87 | 7.97 |
| EBIT Growth(%) | 0 | -38.59 | -67.21 |
| PAT Growth(%) | 0 | -54.98 | -149.6 |
| EPS Growth(%) | 0 | -62.24 | -149.29 |
| Debt/Equity(x) | 0.52 | 0.6 | 0.81 |
| Current Ratio(x) | 1.45 | 1.33 | 1.26 |
| Quick Ratio(x) | 0.97 | 0.89 | 0.82 |
| Interest Cover(x) | 6.81 | 3.45 | 0.65 |
| Total Debt/Mcap(x) | 0 | 0 | 0.67 |
| # | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|---|---|
| Promoter | 34.79 | 34.79 | 34.79 | 34.79 | 35.02 | 35.02 | 35.02 |
| FII | 27.36 | 41.29 | 39.27 | 35.01 | 32.37 | 32.51 | 30.59 |
| DII | 4.86 | 5.27 | 4.98 | 5.49 | 8.02 | 9.68 | 12.12 |
| Public | 32.99 | 18.65 | 20.96 | 24.71 | 24.59 | 22.79 | 22.27 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|---|---|
| Promoter | 41.51 | 41.51 | 41.51 | 41.51 | 46.33 | 46.33 | 46.33 |
| FII | 32.65 | 49.27 | 46.87 | 41.78 | 42.82 | 43.01 | 40.46 |
| DII | 5.8 | 6.29 | 5.94 | 6.55 | 10.61 | 12.8 | 16.04 |
| Public | 39.37 | 22.26 | 25.01 | 29.49 | 32.54 | 30.15 | 29.46 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 119.33 | 119.33 | 119.33 | 119.33 | 132.29 | 132.29 | 132.29 |
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
You May Also Know About
